Specialised - Bleeding Disorders
key details
| Value | £92,500,000 |
|---|---|
| Status | planned |
| Category (CPV) | 33141530 |
| Contract start | 1 Jul 2018 |
| Contract end | 30 Jun 2019 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-17fee10a-d979-4ff2-be14-776496a52cfd |
description
The products to be included in the procurement exercise are:
| Recombinant factor VIIa, | |
| PDFVIII containing vWF concentrate, | |
| PDFIX concentrate, | |
| PD pure vWF concentrate, | |
| PD Factor VIII Inhibitor Bypassing Fraction (FEIBA), | |
| PD Factor XIII concentrate, | |
| PD Protein C Concentrate, | |
| PD Fibrinogen concentrate, | |
| Fresh Frozen Plasma, | |
| PD FX concentrate, | |
| Recombinant Porcine Factor VIII concentrate, | |
| Prothrombin Complex Concentrate, | |
| Emicizumab (humanised bispecific antibody). |
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 31 Jan 2018 | Planning (planning) | · | db1110d5-a4a8-4c3e-a7da-0551561f7c36-195210 |
more from NHS ENGLAND
- Products for the treatment of Haemophilia A · £215,000,000 · 11 May 2023
- NHS Framework Agreement for the supply of products for the treatment of Haemophilia A · £215,000,000 · 26 Apr 2023
- NHS Framework Agreement for the Supply of Human Normal Immunoglobulin & Anti-D Immunoglobulin · £526,598,540 · 3 Feb 2023
- NHS Framework Agreement for the supply of Adult Influenza Vaccines - Secondary Care · £16,000,000 · 22 Jul 2022
- National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHA National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B · £250,000,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the treatment of Haemophilia A · £214,000,000 · 22 Mar 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Purchase of Diathermy · Leeds Teaching Hospitals NHS Trust · £48,000
- Provision of R-Phycoerythrin F(ab)2-specific IgG antibody · Public Health England · £130,000
- NHS Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B · NHS England · £192,000,000
- Provision of R-Phycoerythrin F(ab)2-specific IgG antibody · Public Health England · £44,601
- National Framework Agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders · NHS England · £302,000,000
- HOME DELIVERY OF RECOMBINANT COAGULATION FACTORS FOR HAEMOPHILIA PATIENTS · University Hospitals of North Midlands NHS Trust
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.